Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Acutus Medical Inc (AFIB)
Acutus Medical Inc (AFIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,439
  • Shares Outstanding, K 28,894
  • Annual Sales, $ 16,360 K
  • Annual Income, $ -39,620 K
  • 60-Month Beta 0.95
  • Price/Sales 1.32
  • Price/Cash Flow N/A
  • Price/Book 0.28
Trade AFIB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.26
  • Most Recent Earnings 0.41 on 03/16/23
  • Next Earnings Date 05/11/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 560.80% ( +560.80%)
  • Historical Volatility 86.29%
  • IV Percentile 94%
  • IV Rank 53.22%
  • IV High 990.42% on 09/20/22
  • IV Low 72.10% on 04/22/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 2,211
  • Open Int (30-Day) 2,185

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.66
  • Number of Estimates 1
  • High Estimate -0.66
  • Low Estimate -0.66
  • Prior Year -1.11
  • Growth Rate Est. (year over year) +40.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6500 +6.92%
on 03/29/23
1.5900 -56.29%
on 03/01/23
-0.8550 (-55.16%)
since 02/28/23
3-Month
0.6500 +6.92%
on 03/29/23
1.9600 -64.54%
on 02/07/23
-0.3050 (-30.50%)
since 12/28/22
52-Week
0.4800 +44.79%
on 06/16/22
2.1500 -67.67%
on 07/21/22
-1.1250 (-61.81%)
since 03/28/22

Most Recent Stories

More News
Acutus Medical, Inc. (AFIB) Q4 Earnings and Revenues Surpass Estimates

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 158.57% and 3.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

AFIB : 0.6950 (-6.33%)
INFI : 0.1900 (-1.30%)
Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates

Acutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of 13.25% and 3.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

AFIB : 0.6950 (-6.33%)
MTEM : 0.3346 (+0.94%)
Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LYEL : 2.34 (+5.41%)
AFIB : 0.6950 (-6.33%)
Corcept Therapeutics (CORT) Tops Q3 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of 30.43% and 5.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CORT : 21.77 (-0.37%)
AFIB : 0.6950 (-6.33%)
SHAREHOLDER UPDATE: Glancy Prongay & Murray LLP Appointed Lead Counsel in Securities Class Action Against Acutus Medical, Inc.

Glancy Prongay & Murray LLP (“GPM”) announces that it has been appointed Lead Counsel in the securities class action against Acutus Medical, Inc. (“Acutus” or the “Company”) (NASDAQ: AFIB...

AFIB : 0.6950 (-6.33%)
Acutus Medical, Inc. (AFIB) Q2 2022 Earnings Call Transcript

AFIB earnings call for the period ending June 30, 2022.

AFIB : 0.6950 (-6.33%)
Amneal Pharmaceuticals (AMRX) Lags Q2 Earnings Estimates

Amneal (AMRX) delivered earnings and revenue surprises of -5% and 4.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AMRX : 1.3100 (+3.15%)
AFIB : 0.6950 (-6.33%)
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

AKBA : 0.6050 (+0.95%)
AFIB : 0.6950 (-6.33%)
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company...

AFIB : 0.6950 (-6.33%)
Acutus Medical to Announce Second Quarter 2022 Financial Results

CARLSBAD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving...

AFIB : 0.6950 (-6.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Acutus Medical Inc. is an arrhythmia management company. It focused on the way cardiac arrhythmias are diagnosed and treated. Acutus Medical Inc. is based in Carlsbad, California.

See More

Key Turning Points

3rd Resistance Point 0.9467
2nd Resistance Point 0.8783
1st Resistance Point 0.7867
Last Price 0.6950
1st Support Level 0.6267
2nd Support Level 0.5583
3rd Support Level 0.4667

See More

52-Week High 2.1500
Fibonacci 61.8% 1.5121
Fibonacci 50% 1.3150
Fibonacci 38.2% 1.1179
Last Price 0.6950
52-Week Low 0.4800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar